Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2025-03-26 Regulatory Filings
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces that an abstract concerning the drug IPH4502 has been selected for presentation at the AACR 2025 Annual Meeting. It also mentions a presentation by the CEO at the AACR Oncology Industry Partnering Event. This is a communication intended to inform the public and investors about scientific data presentation and corporate participation in an industry event, rather than a full financial report (like 10-K or IR) or a formal regulatory filing like a proxy statement or earnings release. Since it is an announcement about scientific/corporate activity and not a core financial filing, it best fits the general 'Regulatory Filings' (RNS) category as a broad corporate communication, or potentially an Investor Presentation (IP) if it were the presentation itself, but here it is the *announcement* of the presentation/abstract selection. Given the options, RNS serves as the best general regulatory/corporate announcement fallback for non-standard disclosures like this scientific update press release.
2025-03-26 French
6-K
Foreign Filer Report
2025-03-25 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release announcing the executive team's scheduled participation in an upcoming investor conference ('Life Sciences Van Lanschot Kempen Conference'). It provides details about the conference dates and location, company background, and includes standard forward-looking statements and contact information. This type of announcement, which informs investors about management's schedule for engaging with the market (like attending conferences), does not fit the definitions for formal financial reports (10-K, IR, ER), specific corporate actions (DIV, SHA, POS), or regulatory filings (DEF 14A, DVA). It is best classified as a general communication to investors regarding corporate activity, which aligns most closely with a Regulatory Filing (RNS) as a general announcement, or potentially Investor Presentation (IP) if it were the presentation itself, but since it's just an announcement of attendance, RNS is the most appropriate fallback for non-specific corporate news releases.
2025-03-25 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated March 25, 2025, announcing that members of Innate Pharma's management team will be present at an upcoming investor conference (Life Sciences Van Lanschot Kempen Conference) between April 1 and 3, 2025. This announcement focuses on management's participation in an external investor event, which is a common activity disclosed to investors. This type of communication, detailing management's schedule for engaging with investors, aligns best with the 'Investor Presentation' (IP) category if it were a presentation, or more generally, an announcement related to investor relations activities. Since the core purpose is to inform about management's presence at an investor conference, the 'Investor Presentation' (IP) category, which covers detailed investor-focused materials, is the closest fit among the options, although 'Regulatory Filings' (RNS) could also be considered if it were a mandatory disclosure. Given the context of announcing management's engagement schedule, 'IP' is chosen as it relates directly to investor outreach, even if it's not a formal presentation document itself. However, looking closely at the definitions, 'IP' is for 'Investor Presentation'. A more fitting category for announcing management attendance at a conference is often grouped under general investor communications. Since there isn't a specific 'Investor Conference Attendance Announcement' code, and this is a formal announcement about investor engagement, I will re-evaluate. The document is an announcement about management's schedule for investors. This is a form of investor relations communication. If it were a presentation, it would be IP. If it were a general regulatory update, RNS. Given the focus on management engaging with investors, and lacking a better fit, I will select 'IP' as the closest proxy for investor-facing material announcements, or 'RNS' as a general regulatory announcement. Since it is a formal press release announcing management's schedule for investors, and it is not a financial report, a dividend, or a management change, 'RNS' (Regulatory Filings/General Announcement) is the safest fallback, but 'IP' captures the intent better if we interpret 'Investor Presentation' broadly to cover investor engagement announcements. Let's stick to the definitions strictly. It is not a presentation (IP), nor a management change (MANG). It is an announcement about investor engagement. I will classify it as 'RNS' as a general regulatory/investor announcement that doesn't fit the highly specific financial report codes.
2025-03-25 French
6-K
Foreign Filer Report
2025-03-20 English
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and its primary purpose is to announce a future event: a conference call and webcast scheduled for March 27, 2025, following the release of the "financial results for the full year ending December 31, 2024." This structure—announcing the date and time of a results discussion—is characteristic of an Earnings Release (ER) or a precursor to one. Since it is an announcement about the upcoming discussion of financial results, it aligns best with the Earnings Release (ER) definition, which covers the initial announcement of periodical financial results (key highlights or the event where they are discussed). It is not the full transcript (CT), the full annual report (10-K), or a general regulatory filing (RNS). The document is short and serves as a notification about the results event. FY 2024
2025-03-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.